Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study

Archives of Internal Medicine

Volumn 160, Issue 6, 2002, Pages 761-768

  Heit, John A ^a   Mohr, David N ^a   Silverstein, Marc D ^a,b   Petterson, Tanya M ^a   O'Fallon, W Michael ^a   Melton III, L Joseph ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ARTICLE; DEEP VEIN THROMBOSIS; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

EID: 0343674485     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.6.761     Document Type: Article

References (28)

1. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
2. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
3. Bergqvist D, Jendteg S, Johansen L, Persson U, Ödegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med. 1997;126:454-457.
4. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thromboembolism. N Engl J Med. 1979;301: 855-858.
5. Brandjes DP, Heijboer H, Büller H, deRijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med. 1992;327:1485-1489.
6. Hirsh J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med. 1997;157:2174-2177.
7. Schulman S, Rhedin A-S, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
8. White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 1998;158:1005-1010.
9. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worchester DVT Study. Arch Intern Med. 1991;151:933-938.
10. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992; 340:873-876.
11. Kniffin WD JR, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861-866.
12. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995;155:1031-1037.
13. van Beek EJR, Kuijer PMM, Büller HR, Brandjes DPM, Bossuyt PMM, ten Cate JW. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med. 1997;157:2593-2598.
14. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med. 1997;157:2317-2321.
15. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279: 458-462.
16. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
17. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
18. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clinic Proc. 1996; 71:266-274.
19. Kurland LT, Molgaard DA. The patient record in epidemiology. Sci Am. October 1981;245:54-63.
20. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [published correction appears in Obes Res. 1998;6:464]. Obes Res. 1998;6(suppl 2): 51S-209S.
21. Saerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093-2109.
22. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
23. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
24. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulation therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-398.
25. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
26. Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for Factor V (Factor V Leiden). N Engl J Med. 1997;336:399-403.
27. van den Belt AGM, Sanson B-J, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157: 2227-2232.
28. Schulman S, Svenungsson E, Granqvist S, and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332-338.